The Oncology Institute, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$503M
SG&A
$106M
D&A
$7M
Operating Income
$-36M
EBITDA
$-29M
Interest Expense
$11M
Interest Income
—
Other Income/Expense
$-13M
Pretax Income
$-61M
Tax Provision
$-131K
Net Income
$-61M
Operating Margin
-7.2%
Net Margin
-12.1%
Effective Tax Rate
0.2%
Deferred Tax Assets
$8M
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$76M
NOL Carryforwards
$221M
ETR (Continuing Operations)
0.2%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
Operating Lease Cost
$8M
Revenue YoY Variation
27.8%
Income YoY Variation
40.0%